Management of XXXX in severe @entity409 .

@entity1 @entity82 @entity1956 @entity409 @entity6194 @entity17705 @entity1578 @entity15833 @entity157 @entity393
In the past few decades, @entity6194 ( @entity6194 ) has evolved from a disease that was untreatable and progressive, to one that can be easily controlled with antiviral therapy. However, @entity1 with severe @entity409 still remain difficult to treat despite the availability of highly potent nucleos(t)ide analogs. These include those with underlying @entity82 , severe flares of @entity6194 ( @entity157 ), and for those undergoing liver transplantation. For those with established @entity82 , antiviral therapy should be considered for all, as unpredictable flares can still occur, which can be fatal for those with @entity409 . However, even with effective viral suppression, the development of @entity157 can still occur. For @entity1 with severe flares of @entity6194 , although the use of antiviral can improve long term outcomes, a significant proportion may still die without liver transplantation. The short term prognosis of these @entity1 is dependent on both the severity of flare and underlying pre-existing @entity409 . In @entity1 with decompensated @entity82 , @entity1578 secondary to severe flares, or those with @entity157 , liver transplantation may be curative. After liver transplantation, long term antiviral therapy is required to prevent @entity393 from recurrent @entity1956 . The use of @entity1956 immune globulin (HBIG) in combination with an oral antiviral agent has been the mainstay of post-transplant antiviral regimen for over a decade. With newer and more potent antiviral agents such as @entity15833 and @entity17705 , use of these agents along with HBIG have demonstrated to be effective in preventing significant recurrence in the long term.
